Signal Genetics Inc (NASDAQ:SGNL) Loses Eighty Percent In YOY Value

[[tagnumber 0]][[tagnumber 1]]Signal Genetics Inc (NASDAQ:SGNL) has been having quite a rough time on the charts in 2015. Over the last ten months, SGNL‘s market value has shrunk by a hefty 60% and the downtrend seems as clear as never before. Does Signal Genetics have what it takes to buck the trend and are managers doing anything in this regard, though?[[tagnumber 2]] [[tagnumber 0]]Judging from the news, they are. Having recently signed two Master Service Agreements with leading pharmaceutical enterprises, they are making an effort to popularize SGNL‘s flagship, the so called Myeloma Prognostic Risk Signature, or MyPRS®. The latter is a diagnostic service aimed to help develop new treatments for patients with multiple myeloma. The agreements in question are expected to bring SGNL‘s MyPRS® under the spotlight by featuring it in various clinical trials regarding this rare type of cancer disease.[[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]The aforementioned contracts align with the company‘s objective to build strategic relations with other industry–related companies and are expected to give the stock a boost in the long term. And ‘long‘ seems to be the key word here, for the stock‘s short–term performance is dismal at best. Yesterday, SGNL closed trade at $0.98 per share, up 3.83% from the day before. Yet, the stock still remains dangerously close to its 52–week low of $0.83 reached last Friday.[[tagnumber 2]] [[tagnumber 0]]While the two master service agreements captured earlier this year seem to be a logical step in bringing MyPRS® to the next stage, their impact on the stock‘s market value only lasted for a short while. On an year–over–year basis, SGNL shares are now 80% cheaper. How the stock will perform in the months to come will depend on how well Signal‘s MyPRS® will do in the clinical trials. Updates on that, however, seem unlikely to show up in the immediate future.[[tagnumber 2]]